Luo v. Spectrum Pharmaceuticals, Inc.

CourtDistrict Court, D. Nevada
DecidedJuly 28, 2022
Docket2:21-cv-01612
StatusUnknown

This text of Luo v. Spectrum Pharmaceuticals, Inc. (Luo v. Spectrum Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Luo v. Spectrum Pharmaceuticals, Inc., (D. Nev. 2022).

Opinion

1 2 UNITED STATES DISTRICT COURT 3 DISTRICT OF NEVADA 4

5 Jose Chung Luo, individually and on behalf of all others similarly situated, Case No. 2:21-cv-01612-CDS-BNW 6 Plaintiffs, 7 v.

8 Spectrum Pharmaceuticals, Inc., et al, Order

9 Defendants. 10 11 This is a securities class action case filed brought by Plaintiff Jose Chung Luo on behalf 12 of himself and others who acquired Spectrum securities between December 27, 2018, and August 13 5, 2021. Before the Court are competing motions of appointment to be the lead plaintiff in this 14 securities class action litigation. For the reasons set forth below, International Trading Group, 15 Inc.’s motion for appointment of counsel and for appointment as lead plaintiff (ECF No. 18) are 16 hereby GRANTED. The other motions for appointment (ECF Nos. 15, 16, 17, 20) are DENIED. 17 I. Relevant Background Information 18 On August 31, 2021, Plaintiff Luo filed the complaint identifying the nature of the case as 19 “a federal securities class action on behalf of a class consisting of all persons and entities other 20 than Defendants that purchased or otherwise acquired Spectrum securities between December 21 27, 2018[,] and August 5, 2021.” ECF No. 1 at 2, ¶1. Luo sues under Sections 10(b) and 20(a) of 22 the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. Id. He alleges that Defendants 23 made materially false and misleading statements about Rolontis, a developmental drug that 24 Defendant Spectrum Pharmaceuticals planned to submit to the Food and Drug Administration 1 for approval. Id. at 2-3, ¶4. On August 6, 2021, Spectrum announced receipt of a letter from the 2 FDA regarding Rolontis, which cited deficiencies related to Spectrum’s manufacturing and 3 indicated that re-inspection of Spectrum’s manufacturing facility would be necessary. Id. at 3, ¶5. 4 Luo alleges that this news caused “Spectrum’s stock price [to fall] $0.70 per share, or 21.54%, to 5 close at $2.55 per share on August 6, 2021.” Id. at 3, ¶6. Due to the decline in Spectrum’s stock 6 price, Luo argues that he and other class members have suffered significant losses and damages. 7 Id. at 3, ¶7. 8 On the same day that Luo filed suit, notice was issued pursuant to the Private Securities 9 Litigation Reform Act of 1995 (“PSLRA”) advising potential class members of the claims alleged 10 by Luo and of the 60-day deadline for class members to move to be appointed as lead plaintiff. 11 ECF No. 17-2 at 2-4. 12 On November 1, 2021, the final day of the deadline, five movants filed similar motions for 13 appointment as lead plaintiff and requested this Court’s approval for their selection of counsel. 14 ECF Nos. 15 (Mark Mehalic), 16 (Changyoung Jung), 17 (Mark Kozubal), 18 (International 15 Trading Group, Inc. (“ITG”), 20 (Steven Dunkleberger). Jung, Mehalic, and Dunkleberger 16 subsequently filed non-opposition responses to the other prospective lead plaintiffs’ motions. 17 ECF Nos. 21, 22, 25. 18 The remaining movants, Kozubal and ITG, both assert that they should be appointed 19 lead plaintiff and filed responses and replies to the other’s motions. ECF Nos. 23, 24, 26, 27.1 20 Essentially, the parties dispute what method should be used to calculate whether Kozubal or 21 ITG suffered greater losses. Compare ITG’s Response, ECF No. 23 at 2-3 with Kozubal’s Response, 22 ECF No. 24 at 6-8. Both parties also attack each other’s adequacy to be lead plaintiff in this 23 action. Compare ECF No. 23 at 3 with ECF No. 24 at 8-9.

24 1 Kozubal and ITG both filed their initial motions on November 1, 2021. Both responses were filed on November 15, 2021, and both replies were filed on November 22, 2021. 1 ITG claims that it suffered the greatest loss, claiming an amount of $684,504.22. ECF No. 2 23 at 2. ITG further argues that Kozubal filed a “boilerplate” certification “lack[ing] any 3 substantial information concerning Kozubal” and that the “dearth of information precludes a 4 finding of adequacy.” Id. at 3. 5 Kozubal claims that he lost $314,291.75. ECF No. 17 at 6. Kozubal contends that most of 6 ITG’s losses are uncountable “in-and-out” losses, which when excluded, leave ITG with 7 “compensable losses [of] no more than $54,921.” ECF No. 24 at 8. Kozubal further alleges that 8 “there are practical reasons to refrain from appointing individuals who have primarily ‘in-and- 9 out’ trades as lead plaintiffs” and that such in-and-out trading makes ITG “inadequate and 10 atypical.” Id. 11 ITG replied, asserting that Kozubal has failed to meet his burden to persuade this Court 12 as to why ITG’s “in-and-out” losses are uncountable and that Kozubal inappropriately raised an 13 argument in its response brief. See generally ECF No. 26. Kozubal also replied, asserting that ITG 14 itself inappropriately raised an argument in its response brief. ECF No. 27 at 9-10. 15 II. Legal Standard 16 “A straightforward reading of the statutory language” of 15 U.S.C. § 78u-4(a) “discloses a 17 clear path that the district court must follow in selecting the lead plaintiff.” In re Cavanaugh, 306 18 F.3d 726, 729 (9th Cir. 2002). The Act instructs district courts to select as lead plaintiff the one 19 “most capable of adequately representing the interests of class members.” 15 U.S.C. § 78u- 20 4(a)(3)(B)(i). “The most capable plaintiff – and hence the lead plaintiff – is the one who has the 21 greatest financial stake in the outcome of the case, so long as he meets the requirements of Rule 22 23.” Cavanaugh, 306 F.3d at 729. “In other words, the district court must compare the financial 23 stakes of the various plaintiffs and determine which one has the most to gain from the lawsuit. It 24 must then focus its attention on that plaintiff and determine, based on the information he has 1 provided in his pleadings and declarations, whether he satisfies the requirements of Rule 23(a), 2 in particular those of ‘typicality’ and ‘adequacy.’” Id. at 730 (emphasis in original). If the plaintiff 3 with the largest financial stake in the controversy provides information that satisfies those 4 requirements, then that plaintiff is presumptively most adequate. Id. Other plaintiffs may rebut 5 the presumptive lead plaintiff’s showing that they satisfy Rule 23’s requirements. Id. “If the 6 plaintiff with the greatest financial stake does not satisfy the Rule 23(a) criteria, the court must 7 repeat the inquiry, this time considering the plaintiff with the next-largest financial stake, until 8 it finds a plaintiff who is both willing to serve and satisfies the requirements of Rule 23.” Id. 9 Finally, a straightforward application of the PSLRA mandates that this Court focus 10 solely on the plaintiffs’ financial stake in the case; “so long as the plaintiff with the largest losses 11 satisfies the typicality and adequacy requirements, he is entitled to lead plaintiff status, even if 12 the district court is convinced that some other plaintiff would do a better job.” Id. at 732. 13 III. Analysis 14 The plaintiff with the greatest financial stake in this litigation is ITG. ITG also satisfies 15 the adequacy and typicality requirements of Rule 23. Thus, ITG should be the lead plaintiff in 16 this action.2 17 i. ITG Has Demonstrated the Greatest Financial Stake in this Case 18 ITG has the greatest financial stake in this litigation because it claims greater losses than 19 the other prospective lead plaintiffs. While the Ninth Circuit has no specific formula to 20

21 2 In reaching this decision, I considered only ITG and Kozubal’s motions for appointment as lead plaintiff, their responses, and their replies. Plaintiffs Mehalic, Jung, and Dunkleberger all filed motions of 22 non-opposition and have consented to the granting of ITG’s motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Campbell v. Wood
18 F.3d 662 (Ninth Circuit, 1994)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Buchanan v. United States
15 F.2d 496 (Eighth Circuit, 1926)
Cindy Castillo v. Bank of America, Na
980 F.3d 723 (Ninth Circuit, 2020)
Johnson v. Donaldson
3 F. 22 (U.S. Circuit Court for the District of Southern New York, 1880)
Ferrari v. Gisch
225 F.R.D. 599 (C.D. California, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Luo v. Spectrum Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/luo-v-spectrum-pharmaceuticals-inc-nvd-2022.